



## ASX ANNOUNCEMENT

### ***R&D Tax Incentive***

**Melbourne, 25 May 2015:** Stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the Company has received an R&D Tax Incentive refund of \$281,464 for the 2013/2014 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds of 45% of eligible expenditure on research and development.

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

**CONTACTS:** Dr. Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr. Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)